Ignite Creation Date:
2025-12-26 @ 11:08 AM
Ignite Modification Date:
2026-01-13 @ 8:13 PM
Study NCT ID:
NCT06538012
Status:
RECRUITING
Last Update Posted:
2024-10-15
First Post:
2024-07-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Sponsor:
Essen Biotech
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
ESBI202472
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None